Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have
UroToday.com
125.4K posts
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
Reno, NV
Joined February 2009
- Protecting immune cells before radiation in #ProstateCancer treatment. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >
- Protecting immune cells before radiation in #ProstateCancer treatment. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >
- Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonnews discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have
- Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVAยฎ (NAI) use to include papillary-only BCG-unresponsive bladder cancer. ๐ 82% bladder preservation at 36 months ๐งฌ
- Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have
- Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access
- Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVAยฎ (NAI) use to include papillary-only BCG-unresponsive bladder cancer. ๐ 82% bladder preservation at 36 months ๐งฌ
- Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVAยฎ (NAI) use to include papillary-only BCG-unresponsive bladder cancer. ๐ 82% bladder preservation at 36 months ๐งฌ
- Protecting immune cells before radiation in #ProstateCancer treatment. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >
- Radical prostatectomy vs radiotherapy in high-risk #ProstateCancer: Emulated randomized comparison with individual patient data from two phase III randomized trials. - A new emulated RCT analysis finds that radiotherapy + long-term ADT results in lower distant metastasis rates
- Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access
- Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access
- Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access


















